Darwin AG is a biotechnology company. It is engaged in the field of human genetics. The group also develops and sells personalized dietary supplements and cosmetics. Its brand includes Novodaily; Rootine and Genopedia.
2021
n/a
Last FY Revenue $28.4M
Last FY EBITDA $41.4M
$15.8M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Darwin achieved revenue of $28.4M and an EBITDA of $41.4M.
Darwin expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See Darwin valuation multiples based on analyst estimatesNTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
---|---|---|---|---|---|
Revenue | XXX | $28.4M | XXX | XXX | XXX |
Gross Profit | XXX | $13.9M | XXX | XXX | XXX |
Gross Margin | XXX | 49% | XXX | XXX | XXX |
EBITDA | XXX | $41.4M | XXX | XXX | XXX |
EBITDA Margin | XXX | 146% | XXX | XXX | XXX |
EBIT | XXX | $29.6M | XXX | XXX | XXX |
EBIT Margin | XXX | 104% | XXX | XXX | XXX |
Net Profit | XXX | $20.7M | XXX | XXX | XXX |
Net Margin | XXX | 73% | XXX | XXX | XXX |
Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Darwin's stock price is EUR 30 (or $33).
Darwin has current market cap of EUR 89.4M (or $100M), and EV of EUR 14.1M (or $15.8M).
See Darwin trading valuation dataEV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
---|---|---|---|---|---|---|
$15.8M | $100M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Darwin has market cap of $100M and EV of $15.8M.
Darwin's trades at 0.6x EV/Revenue multiple, and 0.4x EV/EBITDA.
Equity research analysts estimate Darwin's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Darwin's P/E ratio is not available.
See valuation multiples for Darwin and 12K+ public compsLTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
---|---|---|---|---|---|---|
Market cap (current) | $100M | XXX | $100M | XXX | XXX | XXX |
EV (current) | $15.8M | XXX | $15.8M | XXX | XXX | XXX |
EV/Revenue | n/a | XXX | 0.6x | XXX | XXX | XXX |
EV/EBITDA | n/a | XXX | 0.4x | XXX | XXX | XXX |
EV/EBIT | n/a | XXX | 0.5x | XXX | XXX | XXX |
EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
P/E | n/a | XXX | 4.8x | XXX | XXX | XXX |
EV/FCF | n/a | XXX | -0.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialDarwin's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Darwin's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Darwin's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Darwin and other 12K+ public compsLTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
---|---|---|---|---|---|---|
Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
EBITDA Margin | n/a | XXX | 146% | XXX | XXX | XXX |
EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Opex to Revenue | XXX | XXX | -55% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
EV/Revenue | EV/EBITDA | |||||
---|---|---|---|---|---|---|
2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
SynBiotic | XXX | XXX | XXX | XXX | XXX | XXX |
Mega Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
Procter & Gamble Health | XXX | XXX | XXX | XXX | XXX | XXX |
Abbott India | XXX | XXX | XXX | XXX | XXX | XXX |
Sanofi India | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Darwin acquired XXX companies to date.
Last acquisition by Darwin was XXXXXXXX, XXXXX XXXXX XXXXXX . Darwin acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiplesAcquired Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free TrialWhen was Darwin founded? | Darwin was founded in 2021. |
Where is Darwin headquartered? | Darwin is headquartered in Germany. |
Is Darwin publicy listed? | Yes, Darwin is a public company listed on MUN. |
What is the stock symbol of Darwin? | Darwin trades under 7V0 ticker. |
When did Darwin go public? | Darwin went public in 2021. |
Who are competitors of Darwin? | Similar companies to Darwin include e.g. SynBiotic, Mega Lifesciences, Procter & Gamble Health, Abbott India. |
What is the current market cap of Darwin? | Darwin's current market cap is $100M |
Is Darwin profitable? | Yes, Darwin is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.